Highest-materiality recent filing
Goldenwell Biotech adds Ming Zhou to board; CEO Shuang Liu gifts her 20.2% stake
Board appointed Ming Zhou, 57, as a director on October 8, 2026; board now has four members: Shuang Liu, Yang Lee, Hua Xie and Zhou.
Board approved dismissal of Michael Gillespie & Associates, PLLC on September 27, 2026; engaged Privatco CPA Limited on September 22, 2026, which accepted the appointment.
Goldenwell Biotech to restate three quarterly reports over $9,840 legal fee timing errors
Auditor notified company on May 19, 2025 that legal invoice for $9,840 should have been recorded in service periods (May 2024–Sep 2025), not when received.
Goldenwell Biotech's auditor KCCW resigns; Michael Gillespie & Associates appointed
KCCW resigned as independent registered public accounting firm on July 24, 2025, with no disagreements on accounting principles.
Goldenwell Biotech dismisses auditor Michael Gillespie & Associates, engages KCCW
Dismissed Michael Gillespie & Associates on Jan 23, 2025; engagement lasted from Nov 14, 2024.
Goldenwell Biotech dismisses auditor after PCAOB revokes registration; appoints new auditor
Dismissed Yusufali & Associates on Nov 13, 2024, after PCAOB revoked its registration.
Goldenwell Biotech dismisses BF Borgers as auditor, cites going-concern doubt in prior reports
Dismissed BF Borgers CPA PC on May 14, 2024, following board approval.
Goldenwell Biotech dismisses auditor Gillespie & Associates, engages BF Borgers
Dismissed Michael Gillespie & Associates on Sept 8, 2021, effective immediately.
On October 8, 2026, the board of directors of Goldenwell Biotech, Inc. (the “Company”) appointed Ming Zhou as a director.
Max materiality 0.70 · Median 0.57 · Most common event other_material